Company Encyclopedia
View More
name
Amicus Therap
FOLD.US
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company’s commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, a novel two-component treatment program for adults living with late-onset Pompe disease. It has collaboration and license agreement with GlaxoSmithKline to develop and commercialize Galafold. Amicus Therapeutics, Inc.
1.945 T
FOLD.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
BiotechnologyIndustry
Industry Ranking81/394
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE-6.87%D
    • Profit Margin-2.35%D
    • Gross Margin88.49%A
  • Growth ScoreA
    • Revenue YoY21.28%A
    • Net Profit YoY86.57%A
    • Total Assets YoY10.46%B
    • Net Assets YoY28.85%A
  • Cash ScoreC
    • Cash Flow Margin-4257.90%E
    • OCF YoY21.28%A
  • Operating ScoreB
    • Turnover0.72B
  • Debt ScoreD
    • Gearing Ratio73.48%D

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Amicus Therapeutics CEO Sells Shares

    Reporter NameCampbell Bradley LRelationshipPresident and CEO, 10% OwnerTypeSellAmount$146,011SEC FilingForm 4Bradley L. Campbell, President and CEO of Amicus Therapeutics, and a 10% owner, sold 14,587 shares of common stock on December 1, 2025, at a weighted average price of $10.0097 per share, totaling $146,011. Following the transaction, Campbell directly owns 1,137,282 shares of the company. The sale was executed under a Rule 10b5-1 trading plan adopted on September 13, 2024.SEC Filing: AMICUS THERAPEUTICS, INC. [ FOLD ] - Form 4 - Dec. 03, 2025

    TradingView·
    US
    FOLD
    -0.50%
    TradingView·
    US
    FOLD
    -0.50%

    Capital Fund Management S.A. Has $4.37 Million Stake in Amicus Therapeutics, Inc. $FOLD

    Capital Fund Management S.A. increased its stake in Amicus Therapeutics by 144% in Q2, owning 762,698 shares worth $4.37 million. Amicus reported Q3 EPS of $0.17, beating estimates. Insiders sold shares, reducing ownership. Analysts upgraded ratings, with JPMorgan raising the target price to $19.00. Amicus stock opened at $9.80, with a market cap of $3.02 billion.

    Market Beat·
    US
    FOLD
    -0.50%
    Market Beat·
    US
    FOLD
    -0.50%

    Officer Rosenberg Sells 95,621 ($958.5K) Of Amicus Therapeutics Inc [FOLD]

    Ellen Rosenberg, an officer of Amicus Therapeutics Inc, sold 95,621 shares worth $958,476 as disclosed in a Form 4 filed with the SEC. The transactions were executed under a prearranged trading plan. Rosenberg's ending holdings are 522,710 shares.

    Reuters·
    US
    FOLD
    -0.50%
    Reuters·
    US
    FOLD
    -0.50%

    Amicus Therapeutics Executives Sell Shares

    Several executives at Amicus Therapeutics, including Ellen Rosenberg, Bradley L. Campbell, David Michael Clark, and Jeff Castelli, have sold shares of the company according to SEC Form 4 filings. The sales, executed under Rule 10b5-1 trading plans, totaled approximately $2.14 million. The transactions occurred in late November 2025, with the executives selling shares at prices ranging from $10.00 to $10.31 per share.

    TradingView·
    US
    FOLD
    -0.50%
    TradingView·
    US
    FOLD
    -0.50%

    Amicus Therapeutics Chief People Officer David Michael Clark Reports Sale of Common Shares

    David Michael Clark, Chief People Officer of Amicus Therapeutics Inc., reported the sale of company common shares. The original filing is available via EDGAR, the SEC's system. This brief, created by Public Technologies using AI, is for informational purposes and not financial advice.

    Reuters·
    US
    FOLD
    -0.50%
    Reuters·
    US
    FOLD
    -0.50%
    © 2025 Longbridge｜Disclaimer